Evoke Pharma, Inc.: Business Overview, Financials & Competitive Analysis
Evoke Pharma, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Specialty pharma with compelling monopoly position in diabetic gastroparesis but insufficient scale to achieve profitability independently. While GIMOTI demonstrated strong commercial traction with 60%+ YoY growth and extended patent exclusivity, the company faced persistent operating losses and limited scale before acquisition. The acquisition by QOL Medical at a substantial.
What is Evoke Pharma, Inc.'s industry? Evoke Pharma, Inc. (evokepharma.com) operates in Specialty Pharmaceuticals / Gastrointestinal Therapeutics. AskCyborg classifies Evoke Pharma, Inc. under Specialty Pharmaceuticals / Gastrointestinal Therapeutics in its company registry.
Evoke Pharma is a specialty pharmaceutical company focused on gastrointestinal disorders, with its flagship product GIMOTI (metoclopramide nasal spray) for diabetic gastroparesis. The company achieved strong revenue g...
Cyborg Score thesis
Specialty pharma with compelling monopoly position in diabetic gastroparesis but insufficient scale to achieve profitability...
Read the full analyst-debate transcript →Get the Latest Evoke Pharma, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeEvoke Pharma, Inc. Overview
Pro stress-test →Evoke Pharma is a specialty pharmaceutical company focused on gastrointestinal disorders, with its flagship product GIMOTI (metoclopramide nasal spray) for diabetic gastroparesis. The company achieved strong revenue growth momentum through 2025, with Q3 2025 net product sales of $4.3 million, representing 61% year-over-year growth. The company was acquired by QOL Medical for $11.00 per share in December 2025 and delisted from NASDAQ.
Strategic Profile
Pro stress-test →Evoke holds a significant market position as the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults. The company expanded access through partnerships with Omnicell and Brentwood Pharmacy while securing patent protection extending market exclusivity to November 2038. Despite strong product growth, the company faced profitability challenges with operating losses offset by growing top-line momentum.
Competitive Landscape
Pro stress-test →GIMOTI holds a monopoly as the sole FDA-approved nasal spray for acute and recurrent diabetic gastroparesis, competing primarily against older oral metoclopramide formulations and alternative gastroparesis treatments. The competitive advantage rests on novel delivery mechanism and extended patent protection. Limited direct competitors in the nasal spray diabetic gastroparesis space.
Industry Context
Evoke Pharma, Inc. operates in Specialty Pharmaceuticals / Gastrointestinal Therapeutics.
Key facts
Headquarters: Solana Beach, CA, US · Revenue: $16M (2025 guidance)